A detailed history of Capital Impact Advisors, LLC transactions in Alector, Inc. stock. As of the latest transaction made, Capital Impact Advisors, LLC holds 24,562 shares of ALEC stock, worth $106,599. This represents 0.2% of its overall portfolio holdings.

Number of Shares
24,562
Previous 102,381 76.01%
Holding current value
$106,599
Previous $817,000 82.01%
% of portfolio
0.2%
Previous 1.1%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$5.69 - $8.08 $442,790 - $628,777
-77,819 Reduced 76.01%
24,562 $147,000
Q4 2023

Feb 14, 2024

BUY
$3.77 - $8.39 $191,953 - $427,185
50,916 Added 98.93%
102,381 $817,000
Q1 2023

May 23, 2023

SELL
$5.85 - $9.84 $100,397 - $168,874
-17,162 Reduced 25.01%
51,465 $318,000
Q4 2022

Feb 14, 2023

SELL
$6.88 - $9.55 $73,691 - $102,290
-10,711 Reduced 13.5%
68,627 $633,000
Q3 2022

Nov 21, 2022

BUY
$8.19 - $13.2 $54,316 - $87,542
6,632 Added 9.12%
79,338 $624,000
Q2 2022

Aug 15, 2022

BUY
$7.65 - $14.24 $180,142 - $335,323
23,548 Added 47.9%
72,706 $739,000
Q1 2022

May 16, 2022

BUY
$13.02 - $20.78 $276,531 - $441,346
21,239 Added 76.07%
49,158 $701,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $25.54 $540,232 - $713,051
27,919 New
27,919 $577,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $358M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.